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Abstract
Background: Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor that commonly arises in the
skin. It is rare for it to occur in the testes. There are only seven cases of testicular Merkel cell carcinoma reported in
the literature.
Case presentation: A 66-year-old Maori man presented to our hospital with left testicular swelling. His alpha-
fetoprotein and beta-human chorionic gonadotrophin levels were within normal limits. His lactate dehydrogenase
concentration was elevated to 267 U/L. Ultrasound imaging confirmed a large testicular mass, and he underwent
left orchiectomy. His histological examination revealed a neuroendocrine tumor with an immunostaining pattern
suggesting Merkel cell carcinoma. He presented to our hospital again 3 months later with right testicular swelling
that was confirmed on ultrasound sonography to be a tumor. He underwent a right orchiectomy, and his
histological examination revealed metastatic Merkel cell carcinoma. A primary lesion was not identified, and
computed tomographic imaging did not reveal spread to other organs. He received six cycles of adjuvant
carboplatin and etoposide chemotherapy and remained disease-free 18 months after completion of chemotherapy.
Conclusions: Given the paucity of studies, standard adjuvant treatment for testicular Merkel cell carcinoma remains
uncertain, although platinum-based chemotherapy seems to be an appropriate option.
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Background
Merkel cell carcinoma (MCC) is a rare and aggressive
neuroendocrine malignancy that often arises in sun-
exposed skin and predominantly affects the elderly. The
mean ages at diagnosis are 76 years for women and 74
years for men [1]. Immunosuppression caused by solid
organ transplant, human immunodeficiency virus (HIV)
infection, and B-cell lymphoproliferative malignancies is
associated with an increased risk of MCC [2–4]. Although
originally thought to arise from Merkel cells in the skin,
it has been suggested that MCC may instead originate
from skin stem cells or pro-/pre- and pre-B cells [5, 6].
Merkel cell polyoma virus (MCPyV), a double-stranded
deoxyribonucleic acid (DNA) virus, has been linked to the
development of MCC [7] and may have a role to play in
the transformation of pro-/pre- and pre-B cells into MCC.
MCC more commonly occurs in the skin of the head
and neck, followed by the upper limbs and shoulders. It
is uncommon for MCC to have an unknown primary
site [1]. MCC metastasizing to the testis is rare. To date,
there are seven cases of testicular MCC published in the
literature [8–13]. Clinical details of all cases are summa-
rized in Additional file 1: Table S1.
Case presentation
A 66-year-old Maori man presented to our hospital
with a history of an enlarged left testicle of 10 weeks’
duration. His clinical examination revealed nontender
swelling of the left testicle. His alpha-fetoprotein (AFP)
and beta-human chorionic gonadotropin (BHCG) levels
were within normal limits. His lactate dehydrogenase
(LDH) concentration was mildly elevated at 267 U/L
(normal range 120–250 U/L). Ultrasonography of his
testes demonstrated an enlarged left testicle measuring
7 × 5.5 × 4.3 cm with an estimated volume of 87 ml. A
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large, heterogeneous mass involved the entire testicle
with increased vascularity (Fig. 1). The patient’s right
testicle measured 3.7 × 2.5 × 1.8 cm with an estimated
volume of 8.8 ml. He underwent left orchiectomy. The
macroscopic specimen consisted of well-circumscribed
nodular lesions of varying sizes, with the largest meas-
uring 45 × 15 mm and containing solid and gelatinous
components (Fig. 2). Sections of the specimen showed
tumor composed of sheets of small, blue, round cells
divided into nodules by fibrous septae (Fig. 3). Immuno-
staining showed the tumor to be cytokeratin 20 (CK20)-
positive with a typical paranuclear dotlike staining pattern
(Fig. 4). The stain showed a positive result for CD56, a
neuroendocrine marker (Fig. 5), as were CD117 and CK
(paranuclear dots). The result was negative for CK7, pla-
cental alkaline phosphatase (PLAP), CD30, CD20, AFP,
S100, SOX10, prostate-specific antigen (PSA), chromogra-
nin, and thyroid transcription factor 1 (TTF-1). The Ki-67
level was >50 %. This immunostaining pattern raised the
possibility of metastatic MCC.
The patient presented again to our hospital 3 months
later this time with a right testicular mass. Tumor markers,
including LDH, AFP, and BHCG, were within normal
limits. Ultrasonographic imaging demonstrated a new le-
sion in the right testis measuring 3 × 2.6 × 2.3 cm. He
underwent a right orchiectomy, and sections of the speci-
men showed diffuse infiltration of small, blue, round cells.
Immunostains were positive for CD117, CD56, synaptophy-
sin, CK20 (dotlike), and cytokeratin AE1/AE3 (dotlike). The
tumor cells were negative for inhibin, PLAP, PSA, S100,
CD30, CD45, CD3, CD20, TTF-1, and napsin A. The Ki-67
level was 80 %. This pattern was consistent with a poorly
differentiated neuroendocrine tumor in keeping with meta-
static MCC. Detailed histology reports can be found in
Additional files 2 and 3. A primary site was not identified,
and a staging computed tomographic scan did not show
evidence of other metastases. The patient received six
cycles of adjuvant carboplatin and etoposide chemotherapy.
He remained disease-free 18 months following completion
of chemotherapy.
Discussion
It has been suggested that the testes are a sanctuary site
for Merkel cell tumors. It is thought that the occurrence
of MCC metastases in the testes soon after completion
of adjuvant chemotherapy could be due to the presence
of a blood-testis barrier that prevents the eradication of
tumor cells with chemotherapy agents, thus making the
testes a sanctuary site [12]. There are also reports of
isolated testicular recurrences in hematological malig-
nancies, suggesting that the testes are a sanctuary site
[14, 15]. However, in a retrospective analysis of patients
with metastatic germ cell tumors treated with primary
chemotherapy, 43 % had no viable tumor in the testes
Fig. 1 Ultrasound image of the patient’s left testis. The left testis is
replaced by a large heterogenous mass
Fig. 2 Macroscopic image of the left testis. The left testis consists of
well-circumscribed nodular lesions of varying sizes containing solid
and gelatinous components. Scale bar = 20 mm
Fig. 3 High-power image (hematoxylin and eosin-stain, original
magnification ×400) showing small, blue, round cells. Tumor nuclei
have a neuroendocrine appearance with speckled chromatin. A
residual seminiferous tubule is seen at top right
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following delayed orchiectomy, showing that adequate
concentrations of chemotherapeutic agents can be
achieved despite the presence of a blood-testis barrier
[16]. It is interesting to note that our patient developed
testicular MCC in both testes, with an unknown primary
site. It is possible that the primary tumor was eradicated
through immunological surveillance, whereas the blood-
testis barrier allowed tumor cells in the testes to escape
this and to proliferate. Another possibility is that the
primary and metastatic disease were heterogeneous and
had different properties.
Immunohistochemical analysis helps to differentiate
testicular MCC from other malignancies such as meta-
static small cell carcinoma of the lung, small cell pheno-
type melanoma, and lymphoma. Paranuclear dot positivity
for CK20 and CAM5.2 is a typical feature of MCC [17].
MCC is also positive for CK AE1/AE3 and neuroendo-
crine markers, synaptophysin, and chromogranin. Positive
CK20 and negative TTF-1 and CK7 distinguish the tumor
cells from small cell lung carcinoma [18]. Positive staining
for S100, HMB-45, and Melan-A is characteristic of
melanoma. Negative leukocyte common antigen (CD45)
differentiates MCC from lymphoma.
Treatment of early stage MCC is with surgical resec-
tion with 1- to 2-cm margins and sentinel lymph node
mapping and biopsy if there is no clinical evidence of
regional lymph node involvement. Radical lymphadenec-
tomy is recommended if the regional lymph nodes are
involved [19]. Alternatively, definitive lymph node irradi-
ation can be performed because this has been shown to
have efficacy similar to completion lymphadenectomy,
with no difference in overall survival [20]. In a retro-
spective analysis of 6908 patients with MCC, adjuvant
radiation to the resection site was associated with
improved overall survival for stage I-II MCC, whereas
adjuvant chemotherapy did not improve overall survival
for stage III MCC [21]. In another population study of
4815 patients with head and neck MCC, adjuvant che-
moradiation and radiation therapy conferred better
overall survival than surgery alone. A survival benefit
was also demonstrated in the adjuvant chemoradiation
group compared with the adjuvant radiotherapy group
in patients with tumor sizes of at least 3 cm, positive
margins, and male sex [22].
Chemotherapy regimens for metastatic MCC are often
similar to the ones used for high-grade neuroendocrine
cancers and small cell cancers, with a number of agents
showing activity, including combinations of cisplatin,
carboplatin, etoposide, cyclophosphamide, doxorubicin,
vincristine, bleomycin, and 5-fluorouracil. MCC is
regarded as chemotherapy-sensitive, but the duration
of response is short. In one series, the response rates
to chemotherapy were 57 % for metastatic MCC and
69 % for locally advanced MCC, with median overall
survival of 9 months and 24 months, respectively [23].
The main predictor of survival in MCC is tumor stage
at the time of diagnosis. Male sex and tumor size
greater than 2 cm are unfavorable factors [1]. It has
been suggested that low tumor depth, absence of lym-
phovascular invasion, a nodular growth pattern, and
intratumoral lymphocyte infiltration are associated
with a lower risk of death [24, 25]. It has also been
noted that patients with MCPyV DNA-positive tumors
have a favorable prognosis compared with those with
MCPyV DNA-negative tumors [26].
Conclusions
We present a rare case of a patient with testicular MCC
occurring twice with an occult primary tumor. Although
a treatment guideline for MCC has been proposed [19],
there is no guidance on how to manage testicular MCC.
Current treatment is individualized and depends on the
Fig. 4 Positive result for cytokeratin 20 with a typical dotlike pattern
of staining (original magnification ×200)
Fig. 5 Positive result for CD56, a neuroendocrine marker (original
magnification ×200)
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extent of disease at the time of diagnosis. Orchiectomy is
the initial management modality if the disease is localized
to the testes, but the role of adjuvant therapy is yet to
be determined.
Additional files
Additional file 1: Table S1. Clinical details of all known cases of
testicular Merkel cell carcinoma. (XLSX 11 kb)
Additional file 2: Supplemental information on histology 1. (DOC 29 kb)
Additional file 3: Supplemental information on histology 2. (DOC 25 kb)
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